Monica G.
- Country
- Italy
- Department
- U.O. di Oncologia Medica
Research Overview
- Efficacy and Safety of Palbociclib and Fulvestrant in HR+/HER2- Advanced Breast Cancer Post-CDK4/6 Inhibitor Therapy: A Phase II Multicenter Study
- Phase III Randomized Trial of Adjuvant Avelumab in High-Risk Triple Negative Breast Cancer Post-Curative Treatment
- Phase III Randomized Trial of Letrozole Versus Carboplatin and Paclitaxel in Estrogen/Progesterone Receptor-Positive Low-Grade Serous Ovarian Carcinoma
Data & Insights
Has run more than one trial at 41 of 106 partner sites.
Specializations
Breast Cancer Therapeutics
The investigator specializes in treating hormone receptor-positive breast cancer and triple-negative breast cancer, with particular focus on advanced therapeutic approaches.
- Endocrine therapy optimization
- CDK4/6 inhibitor combinations
- Immunotherapy applications
Key interests include integrating chemotherapy with aromatase inhibitors and exploring novel treatment sequences.
Ovarian Cancer Management
Focuses on innovative treatments for epithelial ovarian cancer, particularly in advanced stages and specific subtypes like low-grade serous carcinoma.
- PARP inhibitor therapy
- Targeted maintenance strategies
- Hormone receptor-positive disease
Specializes in personalized treatment approaches based on genetic and molecular markers.
Precision Medicine
Develops targeted therapeutic strategies for homologous recombination deficiency and hormone-dependent cancers.
- Biomarker-driven treatment
- Combination therapy approaches
- Maintenance treatment strategies
Focuses on integrating molecular diagnostics with therapeutic decision-making.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.